New Treatments for GEP-NETS

The incidence of neuroendocrine tumors(NETS) has increased fold over the past 30 years makingit the second most prevalent diagnosis in GI malignanciesRecurrency rate for patients who recieved resection is 100% at ten years changing the treatmentparadigm as this was previously considered curative therapyNot all the patients are the same (individualized treatment)For intestinal neuroendocrine tumor approved evidence based treatments includeocterotide(sandostatine)lanreotide(somatuline,)PRRT,and everolimusFor pancreatic neuroendocrine tumors lanreotide,PRRT,Everolimus,sunitinib,and streptozocine areapprovedMore works remains to be done to identify the right drug combination or sequence to avoidunnecessary toxicity in individualized with neuroendocrine tumors, overcome resistance andimproved outcomeAdjuvant treatment remains an unmet need in patients with high risk of recurrency and high gradeneuroendocrine neoplasmPRRT is promising tool for treatment of GEP-NEN patients